ALKS - Alkermes plc
| Previous Close | 33.42 |
| Open | 33.80 |
| Bid | 34.22 x 1000 |
| Ask | 34.28 x 800 |
| Day's Range | 33.09 - 34.38 |
| 52 Week Range | 32.61 - 71.22 |
| Volume | 310,892 |
| Avg. Volume | 788,715 |
| Market Cap | 5.309B |
| Beta (3Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.90 |
| Earnings Date | Feb 12, 2019 - Feb 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.15 |
- GlobeNewswire•2 days ago
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or “the Company”) (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes’ new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.
- Business Wire•5 days ago
INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or “the Company”) (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes’ new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc, Inc. (ALKS)
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Alkermes plc, Inc. ("Alkermes" or the "Company") ...
- Business Wire•6 days ago
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or “the Company”) (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The FDA issued a briefing document about Alkermes’ new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug.
- GlobeNewswire•6 days ago
Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation of Alkermes plc - ALKS
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc (“Alkermes” or the “Company”) (ALKS) resulting from allegations that Alkermes and/or its executives may have issued materially misleading business information to the investing public. If you purchased Alkermes securities, and/or would like to discuss your legal rights and options, please visit Alkermes Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com. On October 30, 2018, the U.S. Food and Drug Administration (“FDA”) released a briefing document on Alkermes’ New Drug Application for ALKS 5461 ahead of a scheduled FDA advisory committee meeting for the drug.
- Business Wire•6 days ago
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc. resulting from allegations that Alkermes may have issued materially misleading business information to the investing public.
- Motley Fool•9 days ago
Just How Bad Is Alkermes' Depression Drug Setback?
The company's ALKS-5461 failed to win over the FDA's advisory committee this month.
- PR Newswire•12 days ago
Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS
NEW YORK , Nov. 9, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes ...
- Benzinga•12 days ago
The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...
- Motley Fool•13 days ago
Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
Markit•13 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•15 days ago
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, ...
- PR Newswire•15 days ago
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
-- Initial Clinical Data From Ongoing Monotherapy Dose-Escalation Stage of Phase 1 Study to be Presented -- DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation ...
- Simply Wall St.•19 days ago
Is Alkermes plc (NASDAQ:ALKS) Overpaying Its CEO?
Richard Pops became the CEO of Alkermes plc (NASDAQ:ALKS) in 2011. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll consider Read More...
- Benzinga•19 days ago
FDA Committees' Unfavorable Ruling Depresses Alkermes Shares
The Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee jointly recommended not to approve Alkermes’ ALKS 5461. Alkermes remains hopeful that the FDA at large will reach a more favorable conclusion. "We remain steadfast in our commitment to make a meaningful difference in the lives of people suffering with serious mental health conditions, and will continue to work with the FDA as it completes its review of the ALKS 5461 regulatory submission,” Alkermes CEO Richard Pops said in a press release.
- Benzinga•19 days ago
The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
- MarketWatch•20 days ago
Alkermes stock falls after FDA committee votes against depression drug
Alkermes PLC revealed Thursday afternoon that U.S. Food and Drug Administration committees had voted against approval of a prospective drug for major depressive disorder, sending shares plunging in after-hours trading. The FDA does not have to follow the recommendation of its committees, but does take their opinion into consideration in weighing whether to approve a drug. Alkermes said the vote was 21 against approval and two in favor. "We were disappointed and surprised by the FDA's characterization of the safety and efficacy data for ALKS 5461 and the resulting outcome of the Advisory Committee vote," Chief Executive Richard Pops said in Thursday's announcement. Alkermes stock was paused for after-hours trading ahead of the announcement, and when it began trading again at 6:45 p.m. Eastern time, shares dropped about 9%.
- Reuters•20 days ago
Alkermes' depression treatment fails to get FDA panel backing
The decision comes two days after FDA staff reviewers https://bit.ly/2QegxPF flagged abuse potential for the opioid-based depression treatment and raised questions on its efficacy. "I don't feel the evidence that was presented was substantial to show that there was efficacy ... I'm not convinced there is a big enough treatment effect to make a clinical difference," said Terri Warholak, a panel member.
- PR Newswire•20 days ago
Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
DUBLIN, Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the company's New Drug Application (NDA) for ALKS 5461. ALKS 5461 is a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.
- American City Business Journals•20 days ago
Alkermes depression drug in peril after FDA advisory vote
The advisory committee decision is not a final verdict on the drug application, but a negative decision is often a sign that the FDA will reject the drug.
- MarketWatch•20 days ago
Alkermes stock halted as FDA committee considers depression drug
Alkermes PLC shares were halted on Thursday as a U.S. Food and Drug Administration committee met to consider the company's depression drug, ALKS5461. Previously-released briefing documents for the meeting were critical, and Thursday's meeting "kicked off with a bang," Stifel analyst Paul Matteis said, with the regulator discussing "major reservations" about the drug and its data. "While a [failure to approve the drug] is mostly expected, some (albeit a minority) had hoped that the panel - given the massive unmet need in depression, and the precedent of psych panels generally voting positively - could surprise and lean towards flexibility," Matteis said. "However, it seems clear that FDA has essentially made up its mind, and to start has laid a framework that we think will make it very challenging for a positive vote." Alkermes shares have dropped 6.1% over the last three months, compared with a 3.6% decline in the S&P 500 and a 0.9% decline in the Dow Jones Industrial Average .
- PR Newswire•20 days ago
Trading in Alkermes Ordinary Shares Halted Today
DUBLIN, Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), will meet today to review the company's New Drug Application (NDA) for ALKS 5461.
- GlobeNewswire•21 days ago
New Research: Key Drivers of Growth for Alkermes plc, PulteGroup, Las Vegas Sands, Barrick Gold, Avangrid, and Fomento Economico Mexicano S.A.B. de C.V — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 31, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•21 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- CNBC Videos•20 days ago
Alkermes depression drug facing FDA panel, here's what to...
CNBC's Meg Tirrell reports on the new experimental depression drug seeking FDA approval.
